IL-13 Antibody (32116)

Human peripheral blood mononuclear cells (PBMCs) treated with 5 ng/mL Recombinant Human IL‑4 (Catalog # 204-IL) and 10 µg/mL Goat Anti-Human IFN‑ gamma Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-285-NA) for 3 days were stained with Mouse Anti-Human IL‑13 Monoclonal Antibody (Catalog # MAB213) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B) and Mouse Anti-Human CD4 PE-conjugated Monoclonal Antibody (Catalog # FAB3791P). Quadrant markers were set based on control antibody staining (Catalog # MAB002).

Recombinant Human IL‑13 (Catalog # 213-ILB) stimulates proliferation in the TF‑1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL‑13 (10 ng/mL) is neutralized (green line) by increasing concen­trations of Mouse Anti-Human IL‑13 Monoclonal Antibody (Catalog # MAB213). The ND50 is typically 0.15‑0.75 µg/mL.

• Reactivity: Hu
• Applications: Flow, B/N, CyTOF-ready, ELISA(Cap)
• Clone: 32116
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-13 Antibody (32116) Summary

• Immunogen: E. coli-derived recombinant human IL-13
  Gly35-Asn146
  Accession # P35225
• Specificity: Detects human IL-13 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IL13
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Flow Cytometry 2.5 ug/10^6 cells
  • Neutralization 0.15-0.75 ug/mL
• Application Notes: ELISA Capture: Human IL-13 Antibody (Catalog # MAB213)
  ELISA Detection: Human IL-13 Biotinylated Antibody (Catalog # BAF213)
  Standard: Recombinant Human IL-13 (Catalog # 213-ILB)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-13 Antibody (32116)

• ALRHMGC116789
• BHR1interleukin-13
• IL13
• IL-13
• IL-13MGC116788
• interleukin 13
• MGC116786
• NC30
• P600

Background

IL-13 is a 17 kDa immunoregulatory cytokine that plays a key role in the pathogenesis of allergic asthma and atopy. It is secreted by Th1 and Th2 CD4⁺ T cells, NK cells, visceral smooth muscle cells, eosinophils, mast cells, and basophils (1-3). IL-13 circulates as a monomer with two internal disulfide bonds that contribute to a bundled four alpha -helix configuration (4, 5). Mature human IL-13 shares 57%, 59%, and 94% amino acid sequence identity with mouse, rat, and rhesus IL-13, respectively. Despite the low homology, it exhibits cross-species activity between human, mouse, and rat (6, 7). IL-13 has diverse activities on numerous cell types (8). On macrophages, IL-13 suppresses the production of proinflammatory cytokines and other cytotoxic substances. On B cells, IL-13 induces immunoglobulin class switching to IgE, upregulates the expression of MHC class II, CD71, CD72, and CD23, and costimulates proliferation. IL-13 upregulates IL-6 while downregulating IL-1 and TNF-alpha production by fibroblasts and endothelial cells. IL-13 binds with low affinity to IL-13 R alpha 1, triggering IL-13 R alpha 1 association with IL-4 R alpha . This high affinity receptor complex also functions as the type 2 IL-4 receptor complex (9, 10). Additionally, IL-13 binds with high affinity to IL-13 R alpha 2 which is expressed intracellularly, on the cell surface, and as a soluble molecule (11-14). IL-13 R alpha 2 regulates the bioavailability of both IL-13 and IL-4 and is over-expressed in glioma and several bronchial pathologies (10, 15, 16). Compared to wild type IL-13, the atopy-associated R110Q variant of IL-13 elicits increased responsiveness from eosinophils that express low levels of IL-13 R alpha 2 (17).

1. Wills-Karp, M. (2004) Immunol. Rev. 202:175.
2. Nakajima H. and K. Takatsu (2007) Int. Arch. Allergy Immunol. 142:265.
3. McKenzie, A.N. et al. (1993) Proc. Natl. Acad. Sci. USA 90:3735.
4. Moy, F.J. et al. (2001) J. Mol. Biol. 310:219.
5. Eisenmesser, E.Z. et al. (2001) J. Mol. Biol. 310:231.
6. Ruetten, H. and C. Thiemermann (1997) Shock 8:409.
7. Lakkis, F.G. et al. (1997) Biochem. Biophys. Res. Commun. 235:529.
8. Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.
9. Andrews, A.L. et al. (2002) J. Biol. Chem. 277:46073.
10. Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338.
11. Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.
12. Daines, M.O. and G.K. Hershey (2002) J. Biol. Chem. 227:10387.
13. Matsumura, M. et al. (2007) Biochem. Biophys. Res. Commun. 360:464.
14. Tabata, Y. et al. (2007) J. Immunol. 177:7905.
15. Andrews, A.L. et al. (2006) J. Allergy Clin. Immunol. 118:858.
16. Joshi, B.H. et al. (2006) Vitam. Horm. 74:479.
17. Andrews, A-L. et al. (2007) J. Allergy Clin. Immunol. 120:91.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-13 Antibody (MAB213)(10)

Publications using MAB213

• Martin, E;Winter, S;Garcin, C;Tanita, K;Hoshino, A;Lenoir, C;Fournier, B;Migaud, M;Boutboul, D;Simonin, M;Fernandes, A;Bastard, P;Le Voyer, T;Roupie, AL;Ben Ahmed, Y;Leruez-Ville, M;Burgard, M;Rao, G;Ma, CS;Masson, C;Soudais, C;Picard, C;Bustamante, J;Tangye, SG;Cheikh, N;Seppänen, M;Puel, A;Daly, M;Casanova, JL;Neven, B;Fischer, A;Latour, S; Role of IL-27 in Epstein-Barr virus infection revealed by IL-27RA deficiency Nature 2024-03-20 [PMID: 38509369] (Functional Assay, Human)
• Yumiko Tanaka, Mai Yamagishi, Yasutaka Motomura, Takashi Kamatani, Yusuke Oguchi, Nobutake Suzuki et al. Time-dependent cell-state selection identifies transiently expressed genes regulating ILC2 activation Commun Biol 9/6/2023 [PMID: 37673922]
• Irie, M;Kabata, H;Sasahara, K;Kurihara, M;Shirasaki, Y;Kamatani, T;Baba, R;Matsusaka, M;Koga, S;Masaki, K;Miyata, J;Araki, Y;Kikawada, T;Kabe, Y;Suematsu, M;Yamagishi, M;Uemura, S;Moro, K;Fukunaga, K; Annexin A1 is a cell-intrinsic metalloregulator of zinc in human ILC2s Cell reports 2023-06-07 [PMID: 37294636] (Immunoassay, Human)
• Zheng N, Fang J, Xue G et al. Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance Cancer cell 8/15/2022 [PMID: 36027915]
• E Conde, R Bertrand, B Balbino, J Bonnefoy, J Stackowicz, N Caillot, F Colaone, S Hamdi, R Houmadi, A Loste, JBJ Kamphuis, F Huetz, L Guillemina, N Gaudenzio, A Mougel, D Hardy, JN Snouwaert, BH Koller, V Serra, P Bruhns, G Grouard-Vo, LL Reber Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice Nature Communications, 2021-05-11;12(1):2574. 2021-05-11 [PMID: 33976140] (ELISA Capture, Mouse)
• MA Hjort, H Hov, P Abdollahi, EN Vandsemb, UM Fagerli, B Lund, TS Slørdahl, M Børset, TB Rø Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration Exp Hematol Oncol, 2018-04-10;7(0):8. 2018-04-10 [PMID: 29651360] (Neutralization, Human)
• Liu Q, Bradel-Tretheway B, Monreal A, Saludes J, Lu X, Nicola A, Aguilar H Nipah virus attachment glycoprotein stalk C-terminal region links receptor binding to fusion triggering. J Virol, 2014-11-26;89(3):1838-50. 11/26/2014 [PMID: 25428863]
• Scott B. Biering, Andrew Huang, Andy T. Vu, Lindsey R. Robinson, Birgit Bradel-Tretheway, Eric Choi et al. N-Glycans on the Nipah Virus Attachment Glycoprotein Modulate Fusion and Viral Entry as They Protect against Antibody Neutralization Journal of Virology 11/15/2012 [PMID: 22915812]
• Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, Leung DY Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity, 2006-03-01;24(3):341-8. 2006-03-01 [PMID: 16546102] (Neutralization, Human)
• Kiryushko D, Pavon L, Novitskaya V, Sandoval-Lopez G, Soroka V, Eugenia Hernandez M, Klingelhofer J, Loria F, Lukanidin E, Estrada I, Berezin V, Perez M, Bock E, Moreno J, Avila U, Leff P, Anton B, Heinze G Th2 cytokine response in Major Depressive Disorder patients before treatment. J. Neuroimmunol., 2006-02-02;172(1):156-65. 2006-02-02 [PMID: 16457895] (ELISA Development, Human)

Bioinformatics

• Gene Symbol: IL13
• Uniprot:
  • P35225()